Clinical Trial: A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjogren's

U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06928142) titled 'A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjogren's' on March 25.

Brief Summary: This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjogren's disease.

Study Start Date: April 15

Study Type: INTERVENTIONAL

Condition: Sjogren Disease

Intervention: BIOLOGICAL: Sibeprenlimab

400 mg administered SC Q4 weeks

OTHER: Placebo

Administered SC Q4 weeks

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Otsuka Pharmaceutical Development & C...